Randomized controlled trial of memantine in dementia associated with Parkinson's disease.
about
Cognitive training interventions for dementia and mild cognitive impairment in Parkinson’s Diseaseα7 nicotinic ACh receptors as a ligand-gated source of Ca(2+) ions: the search for a Ca(2+) optimumRational pharmacological approaches for cognitive dysfunction and depression in Parkinson's diseaseParkinson's Disease and Cognitive ImpairmentParkinson Disease and Dementia.Treatment of psychosis and dementia in Parkinson's disease.A Risk-Benefit Assessment of Dementia Medications: Systematic Review of the Evidence.The Movement Disorder Society Evidence-Based Medicine Review Update: Treatments for the non-motor symptoms of Parkinson's diseaseTreatment effect of memantine on survival in dementia with Lewy bodies and Parkinson's disease with dementia: a prospective studyEfficacy of memantine in PDD and DLB: an extension study including washout and open-label treatment.Review: management of Parkinson's disease.Treatment of cognitive, psychiatric, and affective disorders associated with Parkinson's disease.Parkinson's disease therapeutics: new developments and challenges since the introduction of levodopa.Neuropsychiatric symptoms in Parkinson's disease with mild cognitive impairment and dementiaParkinson's Disease and Its Management: Part 5: Treatment of Nonmotor Complications.Outcome measures for Parkinson's disease dementia: a systematic review.Treatment of dementia with Lewy bodies and Parkinson's disease dementia.Drug treatments for the neuropsychiatric complications of Parkinson's disease.Summary of the recommendations of the EFNS/MDS-ES review on therapeutic management of Parkinson's disease.The practical management of cognitive impairment and psychosis in the older Parkinson's disease patient.Management of motor and non-motor symptoms in Parkinson's disease.Cognitive impairment and dementia in Parkinson's disease: practical issues and management.Efficacy and safety of cholinesterase inhibitors and memantine in cognitive impairment in Parkinson's disease, Parkinson's disease dementia, and dementia with Lewy bodies: systematic review with meta-analysis and trial sequential analysis.Advances in the treatment of cognitive impairment in Parkinson's disease.Memantine and Kynurenic Acid: Current Neuropharmacological Aspects.Current Treatment Options for Alzheimer's Disease and Parkinson's Disease Dementia.Neuropsychiatric Issues in Parkinson's Disease.Investigational drugs in Phase I and Phase II for Levodopa-induced dyskinesias.Recognition and treatment of neuropsychiatric disturbances in Parkinson's disease.Memantine and reduced time with dyskinesia in Parkinson's Disease.EFNS-ENS Guidelines on the diagnosis and management of disorders associated with dementia.Memantine improves goal attainment and reduces caregiver burden in Parkinson's disease with dementia.Withdrawal of Antidementia Drugs in Older People: Who, When and How?Clinical trials of dementia with Lewy bodies and Parkinson's disease dementia.NMDA antagonists for treating the non-motor symptoms in Parkinson's disease.Late (Complicated) Parkinson's Disease
P2860
Q24188194-17A02C4C-6E8D-4731-A074-C4D862A7827CQ26852967-F159F91A-F667-4E0D-8A1A-BD3A7A7CDA8CQ28084380-E693C593-149E-4F9A-A856-91EA14DF4523Q30239814-9DBD0E60-8683-40E3-A9D3-4CCD257AB21FQ30248574-F6009785-41E0-4942-A355-C4B118A8CDB6Q30358337-96BD1982-3314-47F0-BECC-FD28BF64820DQ33165693-1E980C54-B610-4F34-AFAD-DE17DF173E78Q33607256-A366FCC2-9E68-44DA-8888-34D2DEB9D243Q33879213-FC665F51-8102-4089-8969-71FAA66A2A30Q34128361-49474BA6-3699-4AA9-8205-BAFEBE868A4EQ34332812-9F762E4A-2CB5-4B56-8E1C-1E6F7291F054Q34388686-C6002AED-2AA9-481D-8115-C70E2A4FA3DCQ35614156-274C450C-F9CD-4851-B192-73D2C60D7711Q36219665-D0A4F870-9C76-4316-A5FA-5C334C5E51CBQ36351543-CF998E1F-89A7-40F2-83D6-1F1633586436Q36688859-C2443A97-2167-48C3-8297-A13CC224036AQ37942219-148BE430-4C50-433D-80F4-0BB60E1DCEEAQ38067142-6F7CD6CA-2BB9-4A03-B4AB-5FDBAE85C7E2Q38070888-699F2209-0F05-4594-864C-A7BD65BA3423Q38083586-57CA6A39-79BA-4E36-9D0C-E629043CF349Q38091653-69BD11D0-57F3-4E49-BCC9-C925F8D5AA7DQ38206499-ECF10162-CC52-42AA-B6F8-3F326567DCD5Q38211809-05F96DA4-A2BD-4759-9715-FA25FC8D8918Q38571668-3ACE7B78-09A1-4B22-B6AA-B96ECDF66F9DQ38632327-6F0D9B3D-98F5-4D2C-9AEF-E3AA2899955BQ38661735-9C7CD368-7A99-4440-9E61-BDF35704A5ACQ38799051-093FBD2A-119B-48A9-A200-C7F953FA9A14Q39324877-95427A4A-5B3E-4049-A61F-B8A52AB65D39Q40626246-330D36A7-AA00-40A9-BE82-3F7E34D5F950Q40669186-8889B9E0-37D9-4179-8DC0-E0D5AC7F49AAQ45289583-3C83E086-E22D-425B-AA2B-190733483B5BQ47801241-CA2A94D0-6588-4B0B-9321-9245B2F7258DQ48167336-356D9872-ABA1-4932-9337-BFD515DCDF2AQ48642615-DC6060F5-3357-4504-A132-7ECB67419597Q55474333-28A7C968-020D-48CA-9772-AAAD5AA9A7D0Q58870320-6B60D62E-0D3D-4399-8B68-DD0411174FC1
P2860
Randomized controlled trial of memantine in dementia associated with Parkinson's disease.
description
2009 nî lūn-bûn
@nan
2009 թուականի Յունիսին հրատարակուած գիտական յօդուած
@hyw
2009 թվականի հունիսին հրատարակված գիտական հոդված
@hy
2009年の論文
@ja
2009年論文
@yue
2009年論文
@zh-hant
2009年論文
@zh-hk
2009年論文
@zh-mo
2009年論文
@zh-tw
2009年论文
@wuu
name
Randomized controlled trial of memantine in dementia associated with Parkinson's disease.
@ast
Randomized controlled trial of memantine in dementia associated with Parkinson's disease.
@en
type
label
Randomized controlled trial of memantine in dementia associated with Parkinson's disease.
@ast
Randomized controlled trial of memantine in dementia associated with Parkinson's disease.
@en
prefLabel
Randomized controlled trial of memantine in dementia associated with Parkinson's disease.
@ast
Randomized controlled trial of memantine in dementia associated with Parkinson's disease.
@en
P2093
P2860
P356
P1433
P1476
Randomized controlled trial of memantine in dementia associated with Parkinson's disease.
@en
P2093
E Jane Byrne
Emily Daniel
Iracema Leroi
Ross Overshott
P2860
P304
P356
10.1002/MDS.22495
P407
P577
2009-06-01T00:00:00Z